{"entity":{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","aka":["COSTAR Lung"],"tldr":"A phase 2/3 trial testing Cobolimab in non-small-cell lung cancer, active and no longer recruiting.","summary":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy is a phase 2/3 interventional study registered as NCT04655976, led by GlaxoSmithKline, and active but no longer recruiting on the registry. Official title: A Randomised, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung). Planned enrolment is 758 participants (actual). The study started in 2020-12-08 and primary completion is expected in 2025-06-05. Results have been posted on ClinicalTrials.gov; they are not yet summarised here.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04655976","url":"https://clinicaltrials.gov/study/NCT04655976"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["tim3-blockade"],"targets":[],"drugs":["cobolimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04655976","phase":"2/3","setting":"A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)","sponsor":"GlaxoSmithKline","started":"2020-12-08","startedType":"actual","yearReported":2026,"enrolled":758,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS) (Arm A Versus Arm C)","primary":true,"unit":"months","arms":[{"name":"Cobolimab + Dostarlimab + Docetaxel (Arm A)","n":305,"value":11.9,"note":"95% CI 10.6 to 14.2; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication"},{"name":"Docetaxel (Arm C)","n":152,"value":11.3,"note":"95% CI 9.5 to 13.9"}],"hr":0.85,"ci":[0.68,1.06],"p":"0.079708","source":"https://clinicaltrials.gov/study/NCT04655976?tab=results"},{"endpoint":"Overall Survival (OS) (Arm B Versus Arm C)","primary":true,"unit":"months","arms":[{"name":"Dostarlimab + Docetaxel (Arm B)","n":301,"value":11.8,"note":"95% CI 10.3 to 12.9; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication"},{"name":"Docetaxel (Arm C)","n":152,"value":11.3,"note":"95% CI 9.5 to 13.9"}],"hr":0.96,"ci":[0.77,1.2],"p":"0.369509","source":"https://clinicaltrials.gov/study/NCT04655976?tab=results"},{"endpoint":"Progression Free Survival (PFS)","unit":"months","arms":[{"name":"Cobolimab + Dostarlimab + Docetaxel (Arm A)","n":305,"value":4.4,"note":"95% CI 4.2 to 5.5; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication"},{"name":"Dostarlimab + Docetaxel (Arm B)","n":301,"value":4.2,"note":"95% CI 4.0 to 5.4"},{"name":"Docetaxel (Arm C)","n":152,"value":4.1,"note":"95% CI 2.9 to 4.8"}],"source":"https://clinicaltrials.gov/study/NCT04655976?tab=results"},{"endpoint":"Overall Response Rate (ORR)","unit":"%","arms":[{"name":"Cobolimab + Dostarlimab + Docetaxel (Arm A)","n":305,"value":18.7,"note":"95% CI 14.5 to 23.5; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication"},{"name":"Dostarlimab + Docetaxel (Arm B)","n":301,"value":18.3,"note":"95% CI 14.1 to 23.1"},{"name":"Docetaxel (Arm C)","n":152,"value":14.5,"note":"95% CI 9.3 to 21.1"}],"source":"https://clinicaltrials.gov/study/NCT04655976?tab=results"}]},"route":"/trials/nct04655976/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/"}],"drug":[{"id":"cobolimab","kind":"drug","name":"Cobolimab","route":"/drugs/cobolimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}